Trial Profile
Self-Management of Heparin Therapy - Drug Use Problems and Compliance With Self-Injected Low Molecular Weight Heparin in Ambulatory Care.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary) ; Low molecular weight heparins
- Indications Thromboembolism
- Focus Adverse reactions
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Planned end date changed from 1 Jun 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.